AIM ImmunoTech Inc AIM:NYSE American

Last Price$1.32AMEX Previous Close - Last Trade as of 8:00PM ET 12/03/21
AMEX 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.32 (3)
Ask (Size)$1.34 (8)
Day Low / HighN/A - N/A
Volume324.6 K
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

AIM ImmunoTech Inc ( NYSE MKT LLC )

Price: $1.32
Change: -0.09 (6.38%)
Volume: 324.6 K
8:00PM ET 12/03/2021
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Biocept Inc ( NASDAQ )

Price: $3.77
Change: -0.14 (3.58%)
Volume: 326.4 K
4:00PM ET 12/03/2021
 
 

Evofem Biosciences Inc ( NASDAQ )

Price: $0.38
Change: -0.03 (6.77%)
Volume: 3.0 M
4:00PM ET 12/03/2021
 
 

Genocea Biosciences Inc ( NASDAQ )

Price: $1.12
Change: -0.12 (9.68%)
Volume: 405.3 K
3:59PM ET 12/03/2021
 

Read more news Recent News

AIM ImmunoTech Files for US FDA IND, Fast Track for Mid-Stage Trial of Ampligen for Pancreatic Cancer
8:12AM ET 10/19/2021 MT Newswires

AIM ImmunoTech (AIM) said Tuesday that it has filed for an investigational new drug application as well as fast track status with the US Food and Drug...

AIM ImmunoTech Says Phase 1 Study Shows its Intranasal COVID-19 Treatment Candidate Ampligen is Safe
8:21AM ET 10/06/2021 MT Newswires

AIM ImmunoTech (AIM) said Wednesday data from a phase 1 clinical study of its potential intranasal treatment for COVID-19, Ampligen, indicates its drug...

AIM ImmunoTech Signs Clinical Trial Agreement to Test Ampligen Against Common Cold, Influenza A Viruses
6:52AM ET 9/30/2021 MT Newswires

AIM ImmunoTech (AIM) said Thursday it signed an agreement with Open Orphan subsidiary hVIVO to test its drug Ampligen in a phase 2a human challenge trial...

AIM ImmunoTech Submits Pre-IND Application to FDA for Phase 2 Studies of Ampligen to Treat COVID-19
12:53PM ET 9/28/2021 MT Newswires

AIM ImmunoTech (AIM) has submitted a pre-investigational new-drug application to the US Food and Drug Administration for two separate phase 2 clinical...

View all Commentary and Analysis

AIM ImmunoTech (AIM) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - Slideshow
3:40PM ET 3/16/2021 Seeking Alpha

The Santa Rally May Be Upon Us
2:15PM ET 12/24/2020 Seeking Alpha

Company Profile

Business DescriptionAIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL. View company web site for more details
Address2117 SW Highway 484
Ocala, Florida 34473
Phone+1.352.448.7797
Number of Employees33
Recent SEC Filing11/30/20214
Executive Vice Chairman, President & CEOThomas Kenwood Equels
COO, Secretary & General CounselPeter W. Rodino
Chief Financial OfficerEllen M. Lintal
Chief Scientific & Medical OfficerDavid R. Strayer

Company Highlights

Price Open$1.41
Previous Close$1.41
52 Week Range$1.11 - 3.06
Market Capitalization$63.2 M
Shares Outstanding47.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/30/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.33
Beta vs. S&P 500N/A
Revenue$367.0 K
Net Profit Margin-13,662.70%
Return on Equity-26.50%

Analyst Ratings as of 09/07/2021

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset